|[September 10, 2013]
Research and Markets: TSH Signaling Pathway in Oncology Drug Pipeline Update 2013: 163 Companies Plus Partners Are Now Developing 253 TSH Pathway Targeting Drugs in 915 Developmental Projects
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/97bzfg/tsh_signaling)
has announced the addition of the "TSH
Signaling Pathway in Oncology Drug Pipeline Update 2013" report
to their offering.
Human thyroid stimulating hormone (TSH) exerts its action through
various signaling cascades such as cAMP cascade and the phospholipase C
beta-mediated inositol phosphate generation. Further, it will give
signaling to NF-kappa B, mitogen activated protein kinases, protein
kinase C modules.
There are today 163 companies plus partners developing 253 TSH pathway
targeting drugs in 915 developmental projects in cancer. In addition,
there are 2 suspended drugs and the accumulated number of ceased drugs
over the last years amount to another 100 drugs. TSH Signaling Pathway
In Oncology Drug Pipeline Update lists all drugs and gves you a
progress analysis on each one of them. Identified drugs are linked to
151 different targets. All included targets have been cross-referenced
for the presence of mutations associated with human cancer. To date 149
out of the 151 studied drug targets so far have been recorded with
somatic mutations. The software application lets you narrow in on these
mutations and links out to the mutational analysis for each of the drug
targets for detailed information. All drug targets are further
categorized in the software application by 39 classifications of
molecular function and with pathway referrals to BioCarta, KEGG,
NCI-Nature and NetPath.
Drug Pipeline Update at a Glance:
Includes more than 163 principal companies plus their collaborators.
There is direct access from inside the application to web pages of all
This Drug Pipeline Update contains 253 TSH pathway targeting drugs in
development, which have a total of 915 developmental projects in cancer.
In addition there are suspended and ceased drugs.
Included TSH pathway targeting drugs are also in development for 138
other indications, where of 91 are different cancer indications.
The identity of available biological structures on 123 drug targets was
retrieved from the RCSB Protein Databank for you to easily review the
2348 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/97bzfg/tsh_signaling
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]